US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Oncology Therapeutics, Inc

11.95

+0.97008.83%

Post-market: 12.300.3500+2.93%19:19 EDT

Volume:164.02K

Turnover:1.89M

Market Cap:946.40M

PE:-0.04

High:11.96

Open:11.01

Low:11.01

Close:10.98

52wk High:13.18

52wk Low:8.50

Shares:79.20M

Float Shares:44.60M

Volume Ratio:0.53

T/O Rate:0.37%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-268.5581

EPS(LYR):-511.8002

ROE:--

ROA:--

PB:-4.16

PE(LYR):-0.02

Loading ...

Overview Company News Filings

BRIEF-Bbot Announces Poster Presentations At The 2025 Aacr-Nci-Eortc International Conference

BridgeBio Oncology Therapeutics Announces Poster Presentations on Novel KRAS Inhibitors at 2025 AACR-NCI-EORTC Conference

BridgeBio Oncology Initiated at Outperform by Leerink Partners

BridgeBio Oncology Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating: Target Price $25

THOMSON REUTERS

BridgeBio Oncology Initiated at Buy by HC Wainwright & Co.

HC Wainwright Initiates BridgeBio Oncology Therapeutics at Buy With $27 Price Target

MT Newswires Live

BridgeBio Oncology Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $23.00

THOMSON REUTERS

Oppenheimer Initiates BridgeBio Oncology Therapeutics at Outperform With $23 Price Target

MT Newswires Live

BBOT to Participate in Upcoming September Investor Healthcare Conferences

BridgeBio Oncology Initiated at Outperform by Wedbush

Wedbush Initiates BridgeBio Oncology Therapeutics at Outperform With $25 Price Target

MT Newswires Live

Piper Sandler Initiates BridgeBio Oncology Therapeutics at Overweight With $21 Price Target

MT Newswires Live

Helix Acquisition Corp. II Releases Proforma Financials Highlighting BridgeBio Oncology Therapeutics Merger

Helix Acquisition Corp. II Files Initial Statement of Beneficial Ownership for Director Raymond J. Kelleher

Helix Acquisition Corp. II Retains Over 60% of Trust Account Post-Redemptions, Securing $382 Million for BridgeBio Oncology Merger

Helix Acquisition Corp. Ii Retains More Than 60% of Trust Account After Redemptions in Connection With Business Combination With BridgeBio Oncology Therapeutics

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BBOT/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBOT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","market":"US","secType":"STK","nameCN":"BridgeBio Oncology Therapeutics, Inc","latestPrice":11.95,"timestamp":1760558400000,"preClose":10.98,"halted":0,"volume":164018,"hourTrading":{"tag":"盘后","latestPrice":12.3,"preClose":11.95,"latestTime":"19:19 EDT","volume":2206,"amount":26456.97,"timestamp":1760570355228},"delay":0,"floatShares":44603977,"shares":79196710,"eps":-268.55814,"marketStatus":"Closed","change":0.97,"latestTime":"10-15 16:00:00 EDT","open":11.01,"high":11.96,"low":11.005,"amount":1888184.401008,"amplitude":0.086976,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-268.55814,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760601600000},"marketStatusCode":5,"adr":0,"listingDate":1707454800000,"exchange":"NASDAQ","adjPreClose":10.98,"preHourTrading":{"tag":"盘前","latestPrice":10.98,"preClose":10.98,"latestTime":"08:00 EDT","volume":13,"amount":142.74,"timestamp":1760529610191},"postHourTrading":{"tag":"盘后","latestPrice":12.3,"preClose":11.95,"latestTime":"19:19 EDT","volume":2206,"amount":26456.97,"timestamp":1760570355228},"volumeRatio":0.528797},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBOT\",,,,,undefined,":{"symbol":"BBOT","floatShares":44603977,"roa":"--","roe":"--","lyrEps":-511.800172,"volumeRatio":0.528797,"shares":79196710,"dividePrice":0,"high":11.96,"amplitude":0.086976,"preClose":10.98,"low":11.005,"week52Low":8.5,"pbRate":"-4.16","week52High":13.18,"institutionHeld":0,"latestPrice":11.95,"eps":-268.55814,"divideRate":0,"volume":164018,"delay":0,"ttmEps":-268.55814,"open":11.01,"prevYearClose":10.5,"prevWeekClose":11.82,"prevMonthClose":11.58,"prevQuarterClose":11.58,"fiveDayClose":12.025,"twentyDayClose":10.79,"sixtyDayClose":10.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBOT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-01","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754020800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-05-15","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"BBOT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBOT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBOT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1758340800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BBOT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BBOT","date":"2025-10-14","current":-0.044497,"percent":0.512821,"low":-11.944957,"twenty":-11.205617,"median":-10.377032,"eighty":-9.58363,"high":-8.733947,"avg":-10.394406,"sd":0.839558,"marketCap":907594296},"quantilePoints":[{"date":"2025-08-22","current":-9.544109,"twenty":-10.820609,"median":-9.81087,"eighty":-9.532253,"marketCap":835109579},{"date":"2025-08-29","current":-9.336629,"twenty":-9.787158,"median":-9.514469,"eighty":-9.277349,"marketCap":816955023},{"date":"2025-09-05","current":-9.959071,"twenty":-9.864223,"median":-9.514469,"eighty":-9.247708,"marketCap":871418691},{"date":"2025-09-12","current":-10.047991,"twenty":-10.065775,"median":-9.65773,"eighty":-9.388005,"marketCap":879199215},{"date":"2025-09-19","current":-10.690193,"twenty":-10.20212,"median":-9.78123,"eighty":-9.467045,"marketCap":935391888},{"date":"2025-09-26","current":-11.678196,"twenty":-11.017222,"median":-9.944251,"eighty":-9.487793,"marketCap":1021842155},{"date":"2025-10-03","current":-11.259509,"twenty":-11.190123,"median":-10.077631,"eighty":-9.526325,"marketCap":985207072},{"date":"2025-10-10","current":-11.196152,"twenty":-11.224546,"median":-10.323455,"eighty":-9.563869,"marketCap":979663302},{"date":"2025-10-14","current":-10.372506,"twenty":-11.205617,"median":-10.377032,"eighty":-9.58363,"marketCap":907594296}],"updateTime":1760564101160},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBOT\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575280481","title":"BRIEF-Bbot Announces Poster Presentations At The 2025 Aacr-Nci-Eortc International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575280481","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575280481?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:18","pubTimestamp":1760386722,"startTime":"0","endTime":"0","summary":"BRIEF-Bbot Announces Poster Presentations At The 2025 Aacr-Nci-Eortc International Conference Oct 13 (Reuters) - BridgeBio Oncology Therapeutics Inc BBOT.O:BBOT ANNOUNCES POSTER PRESENTATIONS AT THE 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA8NGP5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"gpt_icon":0},{"id":"2575805052","title":"BridgeBio Oncology Therapeutics Announces Poster Presentations on Novel KRAS Inhibitors at 2025 AACR-NCI-EORTC Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575805052","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575805052?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:05","pubTimestamp":1760385917,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics Inc.  has announced upcoming poster presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, Massachusetts. The company will present data on BBO-11818, an orally bioavailable, highly potent and selective non-covalent pan-KRAS and  inhibitor, which has demonstrated robust anti-tumor activity in KRAS-mutant preclinical models. Additionally, BBOT will present findings on BBO-10203, described as a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction, which inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia. The results will be presented during scheduled poster sessions at the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL9K4K5v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","NDAQ","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","BK4505","BBIO","BK4585","BBOT","LU0314104364.USD","LU2095319765.USD","BK4112","LU2210150020.SGD","IE00BKPKM429.USD","BK4588","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2568557496","title":"BridgeBio Oncology Initiated at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2568557496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568557496?lang=en_us&edition=fundamental","pubTime":"2025-09-17 20:32","pubTimestamp":1758112320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBOT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 17, 2025 08:32 ET (12:32 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBOT"],"gpt_icon":0},{"id":"2568676084","title":"BridgeBio Oncology Therapeutics Inc : Leerink Partners Initiates Coverage With Outperform Rating: Target Price $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2568676084","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568676084?lang=en_us&edition=fundamental","pubTime":"2025-09-17 18:19","pubTimestamp":1758104374,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250917:nFWN3V405H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBOT","BK4139"],"gpt_icon":0},{"id":"2567011133","title":"BridgeBio Oncology Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2567011133","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567011133?lang=en_us&edition=fundamental","pubTime":"2025-09-15 20:08","pubTimestamp":1757938080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBOT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 15, 2025 08:08 ET (12:08 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT","BK4139"],"gpt_icon":0},{"id":"2567056113","title":"HC Wainwright Initiates BridgeBio Oncology Therapeutics at Buy With $27 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2567056113","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567056113?lang=en_us&edition=fundamental","pubTime":"2025-09-15 18:48","pubTimestamp":1757933301,"startTime":"0","endTime":"0","summary":"BridgeBio Oncology Therapeutics (BBOT) has an average rating of buy and mean price target of $24, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BBOT"],"gpt_icon":0},{"id":"2564374354","title":"BridgeBio Oncology Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $23.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2564374354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564374354?lang=en_us&edition=fundamental","pubTime":"2025-09-04 20:14","pubTimestamp":1756988079,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nFWN3UR0OJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BBOT"],"gpt_icon":0},{"id":"2564375505","title":"Oppenheimer Initiates BridgeBio Oncology Therapeutics at Outperform With $23 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2564375505","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564375505?lang=en_us&edition=fundamental","pubTime":"2025-09-04 18:35","pubTimestamp":1756982124,"startTime":"0","endTime":"0","summary":"Oppenheimer Initiates BridgeBio Oncology Therapeutics at Outperform With $23 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","LENZ","BBOT"],"gpt_icon":0},{"id":"2560103964","title":"BBOT to Participate in Upcoming September Investor Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2560103964","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560103964?lang=en_us&edition=fundamental","pubTime":"2025-08-20 20:00","pubTimestamp":1755691200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Aug.  20, 2025  (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malign","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/20/3136340/0/en/BBOT-to-Participate-in-Upcoming-September-Investor-Healthcare-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225283273.USD","LU0267386448.USD","LU1989772840.SGD","LU2347655156.SGD","LU0314104364.USD","LU0795875169.SGD","BK4137","LU0234570918.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0098860793.USD","LU0158827781.USD","LU0320765646.SGD","LU1244550221.USD","LU2023251221.USD","BBOT","LU1720051108.HKD","LU0912757837.SGD","LU1989772923.USD","LU0106831901.USD","LU2357305700.SGD","LU0106261372.USD","LU0971096721.USD","BK4585","LU1244550577.SGD","LU2111349929.HKD","BK4516","LU1732799900.SGD","LU1548497426.USD","LU0795875086.SGD","LU0158827948.USD","BK4581","BK4588","BK4504","LU2133065610.SGD","LU2089284900.SGD","LU1162221912.USD","LU2089283258.USD","BK4127","LU1732800096.USD","LU1244550494.USD","LU2271345857.HKD","HCSG","LU0006306889.USD","LU1074936037.SGD","LU1720051017.SGD","BK4534","LU1668664300.SGD","LU2028103732.USD","LU1363072403.SGD"],"gpt_icon":0},{"id":"2560818613","title":"BridgeBio Oncology Initiated at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2560818613","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560818613?lang=en_us&edition=fundamental","pubTime":"2025-08-18 22:40","pubTimestamp":1755528000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BBOT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 18, 2025 10:40 ET (14:40 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBOT"],"gpt_icon":0},{"id":"2560901666","title":"Wedbush Initiates BridgeBio Oncology Therapeutics at Outperform With $25 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2560901666","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560901666?lang=en_us&edition=fundamental","pubTime":"2025-08-18 19:06","pubTimestamp":1755515208,"startTime":"0","endTime":"0","summary":"Wedbush Initiates BridgeBio Oncology Therapeutics at Outperform With $25 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BBOT","LENZ"],"gpt_icon":0},{"id":"2559193529","title":"Piper Sandler Initiates BridgeBio Oncology Therapeutics at Overweight With $21 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2559193529","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559193529?lang=en_us&edition=fundamental","pubTime":"2025-08-15 19:17","pubTimestamp":1755256630,"startTime":"0","endTime":"0","summary":"Piper Sandler Initiates BridgeBio Oncology Therapeutics at Overweight With $21 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BBOT"],"gpt_icon":0},{"id":"2559605283","title":"Helix Acquisition Corp. II Releases Proforma Financials Highlighting BridgeBio Oncology Therapeutics Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2559605283","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559605283?lang=en_us&edition=fundamental","pubTime":"2025-08-13 18:07","pubTimestamp":1755079641,"startTime":"0","endTime":"0","summary":"Helix Acquisition Corp. II has issued proforma combined financial statements related to its recent merger and acquisition (M&A) transaction with BridgeBio Oncology Therapeutics, Inc. The transaction, which was finalized on August 11, 2025, involved Helix merging with BridgeBio Oncology, resulting in the formation of a combined entity now listed on the Nasdaq under the ticker symbol \"BBOT.\" The financial statements highlight that prior to the closing of this de-SPAC transaction, Helix conducted a private placement financing, raising $260.9 million. The combined company received a total of $366.8 million, accounting for the PIPE financing and unredeemed cash, while also reflecting the transaction costs incurred by Helix. This strategic move aims to bolster the company's mission to develop transformative medicines targeting genetic diseases and cancers.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL92fLmk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HLXB","BK4585","BBOT","BBIO","BK4505","BK4588"],"gpt_icon":0},{"id":"2558693984","title":"Helix Acquisition Corp. II Files Initial Statement of Beneficial Ownership for Director Raymond J. Kelleher","url":"https://stock-news.laohu8.com/highlight/detail?id=2558693984","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558693984?lang=en_us&edition=fundamental","pubTime":"2025-08-12 05:09","pubTimestamp":1754946564,"startTime":"0","endTime":"0","summary":"Helix Acquisition Corp. II filed an initial statement of beneficial ownership with the United States Securities and Exchange Commission. The filing identifies Raymond J. Kelleher as the beneficial owner, who serves as a Director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Helix Acquisition Corp. II published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nNDL9z10TX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HLXB","BBOT"],"gpt_icon":0},{"id":"2557881371","title":"Helix Acquisition Corp. II Retains Over 60% of Trust Account Post-Redemptions, Securing $382 Million for BridgeBio Oncology Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2557881371","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557881371?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:33","pubTimestamp":1754479996,"startTime":"0","endTime":"0","summary":"Helix Acquisition Corp. II Retains Over 60% of Trust Account Post-Redemptions, Securing $382 Million for BridgeBio Oncology Merger. Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, and BridgeBio Oncology Therapeutics have announced that they expect to raise approximately $382 million in gross proceeds from their business combination. This includes $120 million from Helix's trust account and around $261 million from a private placement  transaction. The PIPE financing was led by Cormorant Asset Management and features participation from several prominent investment groups. Helix retained over 60% of its trust account funds following redemptions by public shareholders. The companies plan to move swiftly towards closing the transaction once all conditions are met.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL9xw1MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","BK4139","BK4588","HLXB","LU0314104364.USD","IE00B3QW5Z07.USD","BBIO","BBOT","IE00B64PRP62.GBP","LU2095319765.USD","BK4112","BK4505"],"gpt_icon":0},{"id":"2557350379","title":"Helix Acquisition Corp. Ii Retains More Than 60% of Trust Account After Redemptions in Connection With Business Combination With BridgeBio Oncology Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2557350379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557350379?lang=en_us&edition=fundamental","pubTime":"2025-08-06 19:33","pubTimestamp":1754479980,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nTUA4YBJJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BBOT","BK4505","BBIO","HLXB","BK4588","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}